✦ LIBER ✦

Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer

✍ Scribed by Lin, Yu-Lin; Liau, Jau-Yu; Yu, Shan-Chi; Tseng, Li-Hui; Lin, Liang-In; Liang, Jin-Tung; Lin, Ben-Ren; Hung, Ji-Shiang; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii

Book ID: 122264643
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 423 KB
Volume: 6
Category: Article
ISSN: 1936-5233
DOI: 10.1593/tlo.13166

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

No Survival Benefit from Adding Cetuxima

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

✍ Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yan 📂 Article 📅 2012 🏛 Public Library of Science 🌐 English ⚖ 533 KB

Pharmacogenetic profiling of CD133 is as

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

✍ Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lie 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 401 KB

6106 POSTER Immune-boost Treatment With

6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial

✍ Correale, P.; Rotundo, M.S.; Botta, C.; Guglielmo, A.; Licchetta, A.; Conca, R.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB